A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

References

• Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2006;435:612–9.
   Google Scholar
• Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6: 394–403.
   PubMed Web of Science ®Google Scholar
• Dorner T. Crossroads of B-cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006;77:3–11.
   PubMedGoogle Scholar
• Grimaldi CM, Hicks R, Diamond B. B-cell selection and susceptibility to autoimmunity. J Immunol 2005;174:1775–81.
   Google Scholar
• Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 2006;66:625–39.
   PubMedGoogle Scholar
• Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowka A, Emery P, Close DR, et al. Effi cacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572–81.
   Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. DANCER Study Group. The effi cacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400.
   Google Scholar
• Tanaka Y. Anti-CD20 and other novel biotherapies for systemic lupus erythematosus. APLAR J Rheumatol 2006;9:413–8.
   Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673–7.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44: 1542–5.
   Google Scholar
• Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580–9.
   PubMed Web of Science ®Google Scholar
• Sfi kakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501–13.
   PubMedGoogle Scholar
• van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Sundelin B, Osterborg A, Jacobson SH, et al. Biopsy-verifi ed response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsydocumented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33: 423–7.
   Google Scholar
• Saito K, Nawata M, Nakayamada S, Tokunaga M, Tsukada J, Tanaka Y. Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus 2003;12:798–800.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology 2005;44:176–82.
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Effi cacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470–5.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfi eld NF, et al. The 1982 revised criteria for the classifi cation of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271–7.
   Google Scholar
• Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447–58.
   PubMedGoogle Scholar
• Isenberg DA, Gordon C: From BILAG to BLIPS. Disease activity assessment in lupus: past, present and future. Lupus 2000;9:651–4.
   Google Scholar
• Tanaka Y, Tokunaga M. Rituximab reduces both quantity and quality of B cells in SLE. Rheumatology 2006;45:122–3.
   Google Scholar
• Sanz I, Anolik J. Reconstitution of the adult B-cell repertoire after treatment with rituximab. Arthritis Res Ther 2005;7:175–6.
   PubMedGoogle Scholar
• Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B-cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580–90.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54: 613–20.
   PubMed Web of Science ®Google Scholar
• Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B-cell subsets after transient B-cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54: 2377–86.
   Google Scholar
• Silverman GJ. Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum 2005;52:371–7.
   PubMed Web of Science ®Google Scholar